Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

– Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) –
– Data presented in a platform session at the Annual Meeting of the American Academy of Neurology in Denver, Colorado –

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks